Vincent O’Neill

2.3k total citations
28 papers, 1.2k citations indexed

About

Vincent O’Neill is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Vincent O’Neill has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Vincent O’Neill's work include Peptidase Inhibition and Analysis (12 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (7 papers). Vincent O’Neill is often cited by papers focused on Peptidase Inhibition and Analysis (12 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (7 papers). Vincent O’Neill collaborates with scholars based in United States, United Kingdom and South Korea. Vincent O’Neill's co-authors include Vicente Valero, Adam Brufsky, Sara A. Hurvitz, Hope S. Rugo, Edith A. Perez, Raji Swamy, Ming Lin, O.O. Melnyk, David A. Ramies and Alan Sandler and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Vincent O’Neill

26 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vincent O’Neill United States	8	895	620	477	303	61	28	1.2k
J. A. Engelman United States	12	834 0.9×	1.0k 1.6×	511 1.1×	257 0.8×	119 2.0×	24	1.3k
Elisabetta Campagnoli Italy	10	650 0.7×	446 0.7×	288 0.6×	352 1.2×	66 1.1×	20	952
Jaromı́r Roubec Czechia	9	1.3k 1.4×	1.3k 2.0×	574 1.2×	170 0.6×	75 1.2×	23	1.7k
Marissa N. Balak United States	7	872 1.0×	979 1.6×	701 1.5×	235 0.8×	140 2.3×	7	1.3k
Dana Ghiorghiu United Kingdom	15	808 0.9×	929 1.5×	497 1.0×	171 0.6×	86 1.4×	36	1.4k
Bonne J. Adams United States	11	469 0.5×	264 0.4×	387 0.8×	273 0.9×	38 0.6×	26	824
Georgiana Kuhlmann United States	5	753 0.8×	920 1.5×	500 1.0×	357 1.2×	109 1.8×	6	1.3k
Thaddeus Beck United States	9	885 1.0×	460 0.7×	386 0.8×	208 0.7×	32 0.5×	21	1.1k
L. Fehrenbacher United States	14	1.4k 1.6×	1.4k 2.2×	355 0.7×	229 0.8×	67 1.1×	33	1.7k

Countries citing papers authored by Vincent O’Neill

Since Specialization

Citations

This map shows the geographic impact of Vincent O’Neill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent O’Neill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent O’Neill more than expected).

Fields of papers citing papers by Vincent O’Neill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent O’Neill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent O’Neill. The network helps show where Vincent O’Neill may publish in the future.

Co-authorship network of co-authors of Vincent O’Neill

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent O’Neill. A scholar is included among the top collaborators of Vincent O’Neill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent O’Neill. Vincent O’Neill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weinberg, Benjamin A., Allison A. Fitzgerald, Zoe X. Malchiodi, et al.. (2024). Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.. Journal of Clinical Oncology. 42(17_suppl). LBA4132–LBA4132. 2 indexed citations

Donkor, Moses, et al.. (2023). 661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype. SHILAP Revista de lepidopterología. A753–A753. 1 indexed citations

Aggarwal, Rahul, Jingsong Zhang, Paul Monk, et al.. (2023). First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.. Journal of Clinical Oncology. 41(16_suppl). TPS5109–TPS5109. 1 indexed citations

Chaudhary, Vijay K., et al.. (2022). Endotracheal Intubation at 3,600 Meters Above Sea Level for High-Altitude Pulmonary Edema Followed by Helicopter Evacuation in Nepal. Air Medical Journal. 42(1). 58–60.

Agarwal, Veena R., et al.. (2022). 25 Potential predictive biomarkers for BXCL701 in acute myeloid leukemia (AML). Regular and Young Investigator Award Abstracts. A27–A27. 1 indexed citations

Zhang, Jingsong, Rahul Aggarwal, Scott T. Tagawa, et al.. (2022). BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results.. Journal of Clinical Oncology. 40(6_suppl). 125–125. 2 indexed citations

Tagawa, Scott T., Jingsong Zhang, Paul Monk, et al.. (2022). BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype—Phase 2a interim results.. Journal of Clinical Oncology. 40(6_suppl). 126–126. 2 indexed citations

Tsimberidou, Apostolia M., Veronica R. Holley, Sapna P. Patel, et al.. (2021). Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study.. Journal of Clinical Oncology. 39(15_suppl). 2558–2558. 2 indexed citations

Aggarwal, Rahul, Dan Costin, Vincent O’Neill, et al.. (2020). Safety of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (pembro, anti-PD-1) monoclonal antibody, in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 140–140. 1 indexed citations

10.

Aggarwal, Rahul, Dan Costin, Vincent O’Neill, et al.. (2020). Phase 1b study of BXCL701, a novel small molecule inhibitor of dipeptidyl peptidases (DPP), combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). e17581–e17581. 6 indexed citations

11.

Rha, Sun Young, Seung‐Hoon Beom, Gun Min Kim, et al.. (2019). Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors. Cancer Research. 79(13_Supplement). CT021–CT021. 2 indexed citations

12.

Rha, Sun Young, Seung‐Hoon Beom, Gun Min Kim, et al.. (2019). Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors. Clinical Trials. CT021–CT021. 1 indexed citations

13.

Merli, Pietro, Valentina Bertaina, Federica Galaverna, et al.. (2017). Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) Expand and Persist over Time after Post-Allograft Infusion in Patients Given αβ T-Cell and B-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (αβ haplo-HSCT) Contributing to Accelerate Immune Recovery. Blood. 130. 211–211. 3 indexed citations

14.

Coticchia, Christine M., Ryan J. Sullivan, James Hurley, et al.. (2016). Association of plasma exosomal mRNA changes with long-term durable response to ipilimumab (IPI) in metastatic melanoma (MM) patients.. Journal of Clinical Oncology. 34(15_suppl). 3037–3037. 2 indexed citations

15.

Hurley, James, Vincent O’Neill, Graham Brock, et al.. (2016). Abstract 4969: Exosomal RNA based liquid biopsy detection of androgen receptor variant 7 in plasma from prostate cancer patients. Cancer Research. 76(14_Supplement). 4969–4969. 2 indexed citations

16.

Hurley, James, Lan Hu, Graham Brock, et al.. (2015). Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma.. Journal of Clinical Oncology. 33(15_suppl). e22159–e22159. 4 indexed citations

17.

Sullivan, Ryan J., Vincent O’Neill, Kay Brinkmann, et al.. (2015). Plasma-based monitoring of BRAF mutations during therapy for malignant melanoma (MM) using combined exosomal RNA and cell-free DNA analysis.. Journal of Clinical Oncology. 33(15_suppl). 9017–9017. 8 indexed citations

18.

Brufsky, Adam, Sara A. Hurvitz, Edith A. Perez, et al.. (2011). RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 29(32). 4286–4293. 312 indexed citations

19.

Spigel, David R., Ming Lin, Vincent O’Neill, & John D. Hainsworth. (2008). Final survival and safety results from a multicenter, open‐label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer. 112(12). 2749–2755. 24 indexed citations

20.

Yauch, Robert L., Thomas Januario, David A. Eberhard, et al.. (2005). Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients. Clinical Cancer Research. 11(24). 8686–8698. 415 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact